| Market Capitalization (Millions $) |
1 |
| Shares
Outstanding (Millions) |
40 |
| Employees |
12 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-43 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Viracta Therapeutics Inc
Viracta Therapeutics Inc is a biopharmaceutical company that focuses on developing precision medicines for the treatment of viral-related cancers. The company uses its proprietary viral activation therapy (VAT) platform to target specific viral infections that contribute to the development and progression of certain cancers.
Viracta Therapeutics' novel approach involves combining antiviral agents with immunotherapies to specifically activate and destroy cancer cells that are infected with the Epstein-Barr virus (EBV) or the Kaposi's sarcoma-associated herpesvirus (KSHV). By targeting the virus within the cancer cells, the company aims to disrupt the viral genes responsible for tumor growth and drive a coordinated immune response against the infected cells.
The company's lead product candidate, nanatinostat, is being investigated in clinical trials for the treatment of lymphomas associated with the EBV infection. Viracta Therapeutics aims to expand its pipeline and develop additional therapies targeting other viral-related cancers, leveraging its VAT platform and expertise in precision medicine.
Overall, Viracta Therapeutics Inc is dedicated to developing innovative treatments that harness the power of the immune system to combat viral-related cancers and improve patient outcomes.
Company Address: 2533 S. Coast Hwy. 101, Suite 210 Cardiff 92007 CA
Company Phone Number: 400-8470 Stock Exchange / Ticker: NASDAQ VIRX
|
0.09%